Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.57 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | IKBKB | O14920 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21590329 | 0.91 | PARP1 (0.49) | PARP1PARP2ADRA1A | |
| SCHEMBL30830968 | 0.87 | MYC (0.47) | PARP1IKBKBMEN1KMT2ACHRNB2 | |
| SCHEMBL4345744 | 0.85 | ADRA1A (0.52) | PARP1PARP2ADRA1A | |
| SCHEMBL4356330 | 0.83 | CYP3A4 (0.45) | PARP2ADRA1A | |
| SCHEMBL16446094 | 0.83 | ADRA1A (0.46) | PARP1ADRA1A | |
| SCHEMBL31757029 | 0.82 | PARP1 (0.53) | PARP1PARP2ADRA1A | |
| SCHEMBL363916 | 0.82 | PARP1 (0.53) | PARP1PARP2ADRA1A | |
| SCHEMBL28853811 | 0.81 | PTPN11 (0.43) | PARP1ADRA1AMEN1KMT2A | |
| SCHEMBL161226 | 0.80 | KDM4E (0.50) | PARP1ADRA1AMEN1KMT2A | |
| SCHEMBL3376199 | 0.80 | ADRA1A (0.49) | PARP1ADRA1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2056829-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | Exelixis, Inc. (US) | 2009-05-13 | — | — | EP | claimed |
| WO-2008021389-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS, INC. (US) | 2008-02-21 | — | — | WO | claimed |